Figure 2.
RIOK2 is required for maintaining AML in vivo. (A) Genetic locus and crossing strategy of the Riok2tm1aKOMPWtsi mouse. After rederivation, the mice were crossed with FlpE mice to excise the LacZ+neoR cassette. The progeny of this cross was then crossed with ROSA26::CreERT mice to induce Cre-mediated excision of exons 4 and 5 of Riok2 after tamoxifen treatment. (B) Experimental outline of the Riok2fl/fl R-CreER MLL-AF9 cell line generation. c-Kit+ cells were isolated from a C57/BL6 carrying homozygous floxed Riok2 alleles and transduced with a retrovirus expressing the MLL-AF9 oncogene. After 5 rounds of replating, the cells were transplanted into sublethally irradiated mice and isolated after the mice developed full-blown leukemia. (C) Agarose gel showing PCR products from the amplified region of the floxed Riok2 locus after a 72-hour treatment of Riok2fl/fl R-CreER MLL-AF9 cells with EtOH or OHT (left). Western blot showing RIOK2 protein levels in Riok2fl/fl R-CreER MLL-AF9 cells 72 hours after addition of EtOH or OHT to the culture medium (right). (D) Growth curve of MA9 Riok2fl/fl R-CreER cells after OHT or EtOH addition to the culture medium (n = 3 biological replicates). Multiple unpaired Student t tests were performed to assess statistical significance between the OHT- and EtOH-treated cells. ***P < .001. Error bars represent standard deviation. (E) Experimental overview testing the role of Riok2 in vivo. Riok2fl/fl R-CreER MLL-AF9 cells were transplanted into sublethally irradiated B6/SJL mice. Fourteen days after transplantation, mice were injected with either tamoxifen or oil and monitored for survival. (F) Survival curve of 14 B6-SJL mice receiving transplants of with MA9 Riok2fl/fl R-CreER cells. Dotted lines indicate the time (days 14-19) when the mice were injected daily with either tamoxifen (n = 6) or oil (n = 8). A log-rank (Mantel-Cox) test was performed to assess differences in survival (P = .0003). (G) Spleen weights of mice at the time of death or experimental end point (day 74). Error bars represent standard deviation (SD). A Student t test was performed to assess significance. ****P < .0001.

RIOK2 is required for maintaining AML in vivo. (A) Genetic locus and crossing strategy of the Riok2tm1aKOMPWtsi mouse. After rederivation, the mice were crossed with FlpE mice to excise the LacZ+neoR cassette. The progeny of this cross was then crossed with ROSA26::CreERT mice to induce Cre-mediated excision of exons 4 and 5 of Riok2 after tamoxifen treatment. (B) Experimental outline of the Riok2fl/fl R-CreER MLL-AF9 cell line generation. c-Kit+ cells were isolated from a C57/BL6 carrying homozygous floxed Riok2 alleles and transduced with a retrovirus expressing the MLL-AF9 oncogene. After 5 rounds of replating, the cells were transplanted into sublethally irradiated mice and isolated after the mice developed full-blown leukemia. (C) Agarose gel showing PCR products from the amplified region of the floxed Riok2 locus after a 72-hour treatment of Riok2fl/fl R-CreER MLL-AF9 cells with EtOH or OHT (left). Western blot showing RIOK2 protein levels in Riok2fl/fl R-CreER MLL-AF9 cells 72 hours after addition of EtOH or OHT to the culture medium (right). (D) Growth curve of MA9 Riok2fl/fl R-CreER cells after OHT or EtOH addition to the culture medium (n = 3 biological replicates). Multiple unpaired Student t tests were performed to assess statistical significance between the OHT- and EtOH-treated cells. ***P < .001. Error bars represent standard deviation. (E) Experimental overview testing the role of Riok2 in vivo. Riok2fl/fl R-CreER MLL-AF9 cells were transplanted into sublethally irradiated B6/SJL mice. Fourteen days after transplantation, mice were injected with either tamoxifen or oil and monitored for survival. (F) Survival curve of 14 B6-SJL mice receiving transplants of with MA9 Riok2fl/fl R-CreER cells. Dotted lines indicate the time (days 14-19) when the mice were injected daily with either tamoxifen (n = 6) or oil (n = 8). A log-rank (Mantel-Cox) test was performed to assess differences in survival (P = .0003). (G) Spleen weights of mice at the time of death or experimental end point (day 74). Error bars represent standard deviation (SD). A Student t test was performed to assess significance. ****P < .0001.

Close Modal

or Create an Account

Close Modal
Close Modal